Dr. Faoro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2 Tower Pl
South San Francisco, CA 94080
Summary
- Experienced board-certified medical oncologist and drug developer with more than 15 years of clinical research experience, spanning phase I-IV, with experience filing INDs and BLA/NDAs. Experience in US and Global oncology clinical studies. I have worked on small molecules, and biologics, from signal transduction inhibitors to antibody-drug conjugates and other large molecule constructs.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2005 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
Federal University of Parana Faculty of MedicineClass of 2001
Clinical Trials
- A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) Start of enrollment: 2005 Sep 01
- A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 104 citationsCabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.Marcia S. Brose, Bruce G. Robinson, Steven I. Sherman, Jolanta Krajewska, Chia-Chi Lin
The Lancet. Oncology. 2021-08-01 - 93 citationsEphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.Leonardo Faoro, Patrick A. Singleton, Gustavo M. Cervantes, Frances E. Lennon, Nicholas W. Choong
The Journal of Biological Chemistry. 2010-06-11 - 96 citationsPaxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and InvasionRamasamy Jagadeeswaran, Hanna Surawska, Soundararajan Krishnaswamy, Varalakshmi Janamanchi, A. Craig Mackinnon
Cancer Research. 2008-01-01
Press Mentions
Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical OfficerDecember 13th, 2022- Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical OfficerDecember 13th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
